Asset Acquisition, Share Price

No definition available.

Name:	bmy_AssetAcquisitionSharePrice
Namespace Prefix:	bmy_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Number Of Rights Received Per Share

+ References

No definition available.

+ Details

Name:	bmy_BusinessCombinationContingentValueNumberOfRightsReceived
Namespace Prefix:	bmy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Contingent Value Payout, Period

+ References

No definition available.

+ Details

Name:	bmy_BusinessCombinationContingentValuePayoutPeriod
Namespace Prefix:	bmy_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Contingent Value, Share Price

+ References

No definition available.

+ Details

Name:	bmy_BusinessCombinationContingentValueSharePrice
Namespace Prefix:	bmy_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Contingent and Regulatory Milestone Payments, Maximum Aggregate

+ References

No definition available.

+ Details

Name:	bmy_ContingentAndRegulatoryMilestonePaymentsMaximumAggregate
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

License and Other Arrangements Upfront Payments

+ References

No definition available.

+ Details

Name:	bmy_LicenseAndOtherArrangementsUpfrontPayments
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Licensing Arrangements

+ References

No definition available.

+ Details

Name:	bmy_LicensingArrangementsLineItems
Namespace Prefix:	bmy_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment And Royalty Allocation

+ References

No definition available.

+ Details

Name:	bmy_PaymentAndRoyaltyAllocation
Namespace Prefix:	bmy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Payments to Acquire Productive Assets, Net Of Cash Acquired

+ References

No definition available.

+ Details

Name:	bmy_PaymentsToAcquireProductiveAssetsNetOfCashAcquired
Namespace Prefix:	bmy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage Of Net Sales Payable To Alliance Partner

+ References

No definition available.

+ Details

Name:	bmy_PercentageOfNetSalesPayableToAlliancePartner
Namespace Prefix:	bmy_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Per share price of saleable stock paid or offered to be paid by acquirer in business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479299/805-40-55-10

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-42

+ Details

Name:	us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

+ Details

Name:	us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmy_DiabetesBusinessMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_PhilochemMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_BioArcticMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	bmy_LicensingAndOtherArrangementsAxis=bmy_KeytrudaRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_BristolMyersSquibbMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=bmy_OnoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bmy_RayzeBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AwardTypeAxis=bmy_UnvestedEquityAwardsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bmy_MiratiTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=bmy_A2seventyBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=bmy_KarunaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=bmy_AcquiredIPRDMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS - Narrative (Details) $ / shares in Units, $ in Millions					6 Months Ended		12 Months Ended		36 Months Ended
	May 13, 2025 USD ($) $ / shares	Mar. 18, 2024 USD ($) $ / shares	Feb. 26, 2024 USD ($) $ / shares	Jan. 23, 2024 USD ($) right $ / shares	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2026	Feb. 28, 2025 USD ($)
Licensing Arrangements [Line Items]
Business combination, contingent value, number of rights received \| right				1
Diabetes business - royalties
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner					14.00%		15.00%
Philochem
Licensing Arrangements [Line Items]
License and other arrangements upfront payments					$ 350
Maximum aggregate contingent and regulatory milestone payments					1,000
BioArctic
Licensing Arrangements [Line Items]
License and other arrangements upfront payments					100
Maximum aggregate contingent and regulatory milestone payments										$ 1,300
Keytruda royalties
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner								6.50%
Keytruda royalties \| Forecast
Licensing Arrangements [Line Items]
Percentage of net sales payable to alliance partner									2.50%
Keytruda royalties \| Forecast \| Bristol-Myers Squibb
Licensing Arrangements [Line Items]
Payment and royalty allocation									75.00%
Keytruda royalties \| Forecast \| Ono
Licensing Arrangements [Line Items]
Payment and royalty allocation									25.00%
RayzeBio
Licensing Arrangements [Line Items]
Share price (in usd per share) \| $ / shares			$ 62.50
Total consideration			$ 4,147
Business combination, consideration transferred			3,600
RayzeBio \| Unvested Equity Awards
Licensing Arrangements [Line Items]
Total consideration			$ 274
Mirati Therapeutics
Licensing Arrangements [Line Items]
Share price (in usd per share) \| $ / shares				$ 58.00
Total consideration				$ 4,801
Business combination, consideration transferred				$ 4,100
Business combination, contingent value, share price (in dollars per share) \| $ / shares				$ 12.00
Continent consideration liability				$ 1,000
Business combination, contingent value payout, period				7 years
2seventy bio
Licensing Arrangements [Line Items]
Asset acquisition, share price (in dollars per share) \| $ / shares	$ 5.00
Payments to acquire assets	$ 287
Payments for asset acquisitions, net of cash acquired	$ 114
Karuna
Licensing Arrangements [Line Items]
Asset acquisition, share price (in dollars per share) \| $ / shares		$ 330.00
Payments to acquire assets		$ 14,027
Payments for asset acquisitions, net of cash acquired		$ 12,900
Karuna \| Acquired IPRD
Licensing Arrangements [Line Items]
Payments to acquire assets					$ 12,100	$ 12,100